IN8BIO INC (INAB)
US45674E1091 - Common Stock
IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma
IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma
IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma...
IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are worth diving into on Wednesday morning to get ready for all of the hottest news moving shares today!
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024...
INAB Stock Earnings: IN8bio Misses EPS for Q4 2023
INAB stock results show that IN8bio missed analyst estimates for earnings per share the fourth quarter of 2023.
INAB Stock Earnings: IN8bio Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips IN8bio (NASDAQ:INAB) just reported results for the fourth quarter of 2023.IN8bi...
IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024
IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024...
IN8bio to Present at Upcoming Investor Conferences
IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology
Peer-reviewed publication discusses current strategy and future direction of new treatment for glioblastoma using novel gamma-delta T cell based adoptive...
IN8bio files to sell 42.7M shares for holders (NASDAQ:INAB)
IN8bio (INAB) files prospectus for resale of 42.7 million common shares by selling stockholders, clarifying it is not an offer to sell securities.
In8bio stock jumps 11% following clinical update (NASDAQ:INAB)
Shares of IN8bio (INAB) jumped 11% after the company issued an update on its clinical pipeline. Read more here.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic on Wednesday and we're starting the day with a breakdown of the biggest ones worth watching!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Checking out the biggest pre-market stock movers for Tuesday is the perfect way to get ready for another busy day of trading!
IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia
Durable complete remission (CR) achieved in 100% of treated patients, including high-risk and relapsed acute myeloid leukemia (AML) patients and those who...
IN8bio prices its $46.9M in private placement (NASDAQ:INAB)
IN8bio announces pricing of $46.9M private placement; units sold at $1.22 per unit with series A warrants priced at $1.25 and series B warrants at $1.5.
IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement
Initial closing of $14.4 million to support operational execution and extend cash runway into 2025 with potential for up to $32.5 million in additional capital at increasing valuations
IN8bio Appoints Dr. Corinne Epperly to Board of Directors
Internationally recognized immuno-oncology and cell therapy executive with 20 years of experience in innovative immunotherapies for solid and hematological...
IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia
Event will follow the presentation of INB-100 data in patients with hematologic malignancies at the American Society of Hematology (ASH) 65th Annual...
IN8bio’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma
All patients treated with INB-200 who completed mandated doses to date have exceeded a progression-free survival (PFS) of seven months Most patients...